

## 1. NAME OF THE MEDICINAL PRODUCT

Veletri® 0.5 mg, Powder for Solution for Infusion

Veletri® 1.5 mg, Powder for Solution for Infusion

## 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

### Veletri® 0.5 mg, Powder for Solution for Infusion

Each vial contains 0.531 mg epoprostenol sodium equivalent to 0.5 mg epoprostenol

One mL of reconstituted solution contains 0.1 mg epoprostenol (as epoprostenol sodium) (0.5 mg epoprostenol in 5 mL of solvent).

### Veletri® 1.5 mg, Powder for Solution for Infusion

Each vial contains 1.593 mg epoprostenol sodium equivalent to 1.5 mg epoprostenol

One mL of reconstituted solution contains 0.3 mg epoprostenol (as epoprostenol sodium) (1.5mg epoprostenol in 5 mL of solvent).

Excipient(s) with known effect: sodium, (0.03 mg for 0.5 mg/vial and 0.09 mg for 1.5 mg/vial)

For the full list of excipients, see section 6.1.

## 3. PHARMACEUTICAL FORM

Powder for solution for infusion

White to off-white powder

For the pH of the diluted solution see section 4.4

## 4. CLINICAL PARTICULARS

### 4.1 Therapeutic indications

Veletri® is indicated for:

Pulmonary Arterial Hypertension.

Veletri® is indicated for the treatment of pulmonary arterial hypertension (PAH) (idiopathic or heritable PAH and PAH associated with connective tissue diseases) in patients with WHO Functional Class III–IV symptoms to improve exercise capacity (see section 5.1).

### 4.2 Posology and method of administration

#### Posology

Veletri® is only indicated for continuous infusion by intravenous route.

Treatment should only be initiated and monitored by a physician experienced in the treatment of pulmonary arterial hypertension.

#### Short-term (acute) dose ranging:

This procedure should be conducted in a hospital with adequate resuscitation equipment.

A short-term dose-ranging procedure administered via either a peripheral or central venous line is required to determine the long-term infusion rate. The infusion is initiated at 2 ng/kg/min and increased by increments of 2 ng/kg/min every 15 min or longer until maximum haemodynamic benefit or dose-limiting pharmacological effects are elicited.

If the initial infusion rate of 2 ng/kg/min is not tolerated, a lower dose that is tolerated by the patient should be identified.

#### Long-term continuous infusion:

Long-term continuous infusion of Veletri<sup>®</sup> should be administered through a central venous catheter. Temporary peripheral i.v. infusions may be used until central access is established. Long-term infusions should be initiated at 4 ng/kg/min less than the maximum tolerated infusion rate determined during short-term dose-ranging. If the maximum tolerated infusion rate is 5 ng/kg/min or less, the long-term infusion should be started at 1ng/kg/min.

#### Dosage adjustments:

Changes in the long-term infusion rate should be based on persistence, recurrence or worsening of the patient's symptoms of pulmonary arterial hypertension or the occurrence of adverse reactions due to excessive doses of Veletri<sup>®</sup>.

In general, the need for increases in dose from the initial long-term dose should be expected over time. Increases in dose should be considered if symptoms of pulmonary arterial hypertension persist, or recur after improving. The infusion rate should be increased by 1 to 2 ng/kg/min increments at intervals sufficient to allow assessment of clinical response; these intervals should be at least 15 min. Following establishment of a new infusion rate, the patient should be observed, and erect and supine blood pressure and heart rate monitored for several hours to ensure that the new dose is tolerated.

During long-term infusion, the occurrence of dose-related pharmacological events similar to those observed during the dose-ranging period may necessitate a decrease in infusion rate, but the adverse reactions may occasionally resolve without dosage adjustment. Dosage decreases should be made gradually in 2 ng/kg/min decrements every 15 min or longer until the dose-limiting effects resolve. Abrupt withdrawal of Veletri<sup>®</sup> or sudden large reductions in infusion rates should be avoided due to the risk of potentially fatal rebound effect (see section 4.4). Except in life-threatening situations (e.g. unconsciousness, collapse, etc.), infusion rates of Veletri<sup>®</sup> should be adjusted only under the direction of a physician.

#### *Elderly*

There is no specific information on the use of Veletri<sup>®</sup> in patients over 65 years for pulmonary arterial hypertension. In general, dose selection for an elderly patient should be made carefully, reflecting the greater frequency of decreased hepatic, renal (in the case of pulmonary arterial hypertension) or cardiac function and of concomitant disease or other medicine therapy.

#### *Paediatric population*

The safety and efficacy of Veletri<sup>®</sup> in children have not yet been established.

#### Method of administration

Veletri<sup>®</sup> long-term administration is administered via intravenous route through central venous catheter using an ambulatory infusion pump. The patient must be adequately trained in all aspects of care of the central venous catheter, in the aseptic preparation of the Veletri<sup>®</sup> intravenous injectable solution, and in the preparation and change of the drug delivery reservoir of the infusion pump, and the extension set.

Suitable ambulatory pumps to be used for the administration of Veletri<sup>®</sup> are provided in section 6.6.

### *Reduction of the risk of catheter-related blood-stream infection*

Particular attention should be given to the recommendations in section 4.4 and the following as this should help to reduce the risk of catheter-related blood-stream infections.

The care of the central venous catheter and the catheter exit site should follow established medical principles.

Only extension sets with an in-line 0.22 micron filter placed between the infusion pump and the central venous catheter must be used. It is recommended to use filters with a hydrophilic polyethersulfone membrane. The extension set and the in-line filter must be changed at least every 48 hours (see section 6.6).

### *Preparation of Veletri® intravenous injectable solution:*

The reconstituted solution should be examined prior to further dilution. Its use is forbidden in the presence of discolouration or particles. Reconstituted solutions should be immediately further diluted to the final concentration.

For further instructions on reconstitution and dilution of the medicinal product before administration, see section 6.6.

Veletri® must not be administered as a bolus injection.

## **4.3 Contraindications**

Veletri® is contraindicated in patients:

- with known hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
- with congestive heart failure arising from severe left ventricular dysfunction.
- Veletri® must not be used chronically in patients who develop pulmonary oedema during dose-ranging.

## **4.4 Special warnings and precautions for use**

The pH of the diluted “ready-to-use solution” decreases with dilution, and ranges from 12.0 for a concentration of 90,000 ng/mL, 11.7 for a concentration of 45,000 ng/mL to 11.0 for a concentration of 3,000 ng/mL. Therefore, peripheral intravenous use should be restricted to short duration only, using low concentrations.

Because of the high pH of the final infusion solutions, care should be taken to avoid extravasation during their administration and consequent risk of tissue damage.

The medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially sodium free.

Veletri® is a potent pulmonary and systemic vasodilator. The cardiovascular effects during infusion disappear within 30 min of the end of administration.

Veletri® is a potent inhibitor of platelet aggregation, therefore an increased risk for haemorrhagic complications should be considered, particularly for patients with other risk factors for bleeding (see section 4.5).

If excessive hypotension occurs during administration of Veletri®, the dose should be reduced or the infusion discontinued. Hypotension may be profound in overdose and may result in loss of consciousness (see section 4.9).

Blood pressure and heart rate should be monitored during administration of Veletri®.

Veletri® may either decrease or increase heart rate. The change is thought to depend on both the basal heart rate and the infusion rate of Veletri® administered.

The effects of Veletri<sup>®</sup> on heart rate may be masked by concomitant use of drugs which affect cardiovascular reflexes.

Extreme caution is advised in patients with coronary artery disease.

Elevated serum glucose levels have been reported (see section 4.8).

The solvent contains no preservative; consequently a vial should be used once only and then discarded

Some patients with pulmonary arterial hypertension have developed pulmonary oedema during dose-ranging, which may be associated with pulmonary veno-occlusive disease. Veletri<sup>®</sup> must not be used chronically in patients who develop pulmonary oedema during dose initiation (see section 4.3).

Abrupt withdrawal or interruption of infusion must be avoided, except in life-threatening situations. An abrupt interruption of therapy can induce a rebound of pulmonary arterial hypertension, resulting in dizziness, asthenia, increased dyspnoea, and may lead to death (see section 4.2).

Veletri<sup>®</sup> is infused continuously through a permanent indwelling central venous catheter via a small, portable infusion pump. Thus, therapy with Veletri<sup>®</sup> requires commitment by the patient to sterile drug reconstitution, drug administration, care of the permanent central venous catheter, and access to intense and ongoing patient education.

Aseptic conditions must be adhered to in preparing the drug and in the care of the catheter. Even brief interruptions in the delivery of Veletri<sup>®</sup> may result in rapid symptomatic deterioration. The decision to administer Veletri<sup>®</sup> for pulmonary arterial hypertension should be based upon the patient's understanding that there is a high likelihood that therapy with Veletri<sup>®</sup> will be needed for prolonged periods, possibly years, and the patient's ability to accept and care for a permanent i.v. catheter and infusion pump should be carefully considered.

#### **4.5 Interaction with other medicinal products and other forms of interaction**

When Veletri<sup>®</sup> is administered to patients receiving concomitant anticoagulants, standard anticoagulant monitoring is advisable.

The vasodilator effects of Veletri<sup>®</sup> may augment or be augmented by concomitant use of other vasodilators.

As reported with other prostaglandin analogues, Veletri<sup>®</sup> may reduce the thrombolytic efficacy of tissue plasminogen activator (t-PA) by increasing hepatic clearance of t-PA.

When NSAIDs or other drugs affecting platelet aggregation are used concomitantly, there is the potential for Veletri<sup>®</sup> to increase the risk of bleeding.

Patients on digoxin may show elevations of digoxin concentrations after initiation of therapy with Veletri<sup>®</sup>, which – although transient – may be clinically significant in patients prone to digoxin toxicity.

#### **4.6 Fertility, pregnancy and lactation**

##### **Pregnancy**

There is limited data from the use of epoprostenol in pregnant women.

Animal studies did not indicate harmful effects with respect to reproductive toxicity (see section 5.3).

Given the absence of alternative medicines, epoprostenol can be used in women who choose to continue their pregnancy, despite the known risk of pulmonary arterial hypertension during pregnancy.

## **Breast-feeding**

It is unknown if epoprostenol or its metabolites are excreted in human milk. A risk to the breastfeeding child cannot be excluded. Breastfeeding should be discontinued during treatment with Veletri®.

## **Fertility**

There are no data on the effects of epoprostenol on fertility in humans. Reproductive studies in animals have shown no effects on fertility (see section 5.3).

### **4.7 Effects on ability to drive and use machines**

Pulmonary arterial hypertension and its therapeutic management may affect the ability to drive and operate machinery.

There are no data regarding the effect of Veletri® on the ability to drive or operate machinery.

### **4.8 Undesirable effects**

Adverse events are listed below by system organ class and frequency. Frequencies are defined as follows: very common  $\geq 1/10$  ( $\geq 10\%$ ); common  $\geq 1/100$  and  $< 1/10$  ( $\geq 1\%$  and  $< 10\%$ ); uncommon  $\geq 1/1000$  and  $< 1/100$  ( $\geq 0.1\%$  and  $< 1\%$ ); rare  $\geq 1/10,000$  and  $< 1/1000$  ( $\geq 0.01\%$  and  $< 0.1\%$ ); very rare  $< 1/10,000$  ( $< 0.01\%$ ) and not known (cannot be estimated from the available data).

<b>Infections and Infestations</b>	
Common	Sepsis, septicaemia (mostly related to delivery system for Veletri®) <sup>1</sup>
<b>Blood and Lymphatic System Disorders</b>	
Common	Decreased platelet count, bleeding at various sites (e.g. pulmonary, gastrointestinal, epistaxis, intracranial, post-procedural, retroperitoneal)
Unknown	Splenomegaly, Hypersplenism
<b>Endocrine Disorders</b>	
Very rare	Hyperthyroidism
<b>Psychiatric Disorders</b>	
Common	Anxiety, nervousness
Very rare	Agitation
<b>Nervous System Disorders</b>	
Very common	Headache
<b>Cardiac Disorders</b>	
Common	Tachycardia <sup>2</sup> , bradycardia <sup>3</sup> ,
Not known	High output cardiac failure
<b>Vascular Disorders</b>	
Very common	Facial flushing (seen even in the anaesthetised patient)
Common	Hypotension
Very rare	Pallor
Not known	Ascites
<b>Respiratory, thoracic and mediastinal disorders</b>	
Unknown	Pulmonary oedema
<b>Gastrointestinal Disorders</b>	
Very common	Nausea, vomiting, diarrhoea
Common	Abdominal colic, sometimes reported as abdominal discomfort
Uncommon	Dry mouth
<b>Skin and Subcutaneous Tissue Disorders</b>	
Common	Rash

Uncommon	Sweating
<b>Musculoskeletal and Connective Tissue Disorders</b>	
Very common	Jaw pain
Common	Arthralgia
<b>General Disorders and Administration Site Conditions</b>	
Very common	Pain (unspecified)
Common	Pain at the injection site*, chest pain
Rare	Local infection*
Very rare	Erythema over the infusion site*, occlusion of the long i.v. catheter*, lassitude, chest tightness
<b>Investigations</b>	
Unknown	Blood glucose increased
* Associated with the delivery system for epoprostenol	
<sup>1</sup> Catheter-related infections caused by organisms not always considered pathogenic (including micrococcus) have been reported.	
<sup>2</sup> Tachycardia has been reported as a response to epoprostenol at doses of 5 ng/kg/min and below.	
<sup>3</sup> Bradycardia, sometimes accompanied by orthostatic hypotension, has occurred in healthy volunteers at doses of epoprostenol greater than 5 ng/kg/min. Bradycardia associated with a considerable fall in systolic and diastolic blood pressure has followed i.v. administration of a dose of epoprostenol equivalent to 30 ng/kg/min in healthy conscious volunteers.	

#### Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system.

#### **4.9 Overdose**

The main feature of overdose is likely to be hypotension.

In general, events seen after overdose of Veletri<sup>®</sup> represent exaggerated pharmacological effects of the drug (e.g. hypotension and complications of hypotension).

If overdose occurs, reduce the dose or discontinue the infusion and initiate appropriate supportive measures as necessary; for example, plasma volume expansion and/or adjustment to pump flow.

### **5. PHARMACOLOGICAL PROPERTIES**

#### **5.1 Pharmacodynamic properties**

Pharmacotherapeutic group: Antithrombotic Agents; Platelet aggregation inhibitors excl. heparin, ATC code: B01AC09

The pH value of Veletri<sup>®</sup> is higher than the pH of other epoprostenol products.

Compared to other epoprostenol diluted solutions, which are buffered with glycine, Veletri<sup>®</sup> contains l-arginine, at lower buffering capacity. This leads to a broader range of pH values of the diluted solution. The pH decreases with dilution from 12.0 at a concentration of 90,000 ng/mL, 11.7 at a concentration of 45,000 ng/mL to 11.0 at a concentration of 3,000 ng/mL.

The studies described below under subheading “Pharmacodynamic effects” refer to studies performed with a solution of epoprostenol buffered with glycine and with a pH between 10.3 and 10.8 (Flolan).

#### Mechanism of action

Epoprostenol Sodium, the monosodium salt of epoprostenol, a naturally occurring prostaglandin produced by the intima of blood vessels. Epoprostenol is the most potent inhibitor of platelet aggregation known. It is also a potent vasodilator.

Many of the actions of epoprostenol are exerted via the stimulation of adenylate cyclase, which leads to increased intracellular levels of cyclic adenosine 3'5' monophosphate (cAMP). A sequential stimulation of adenylate cyclase, followed by activation of phosphodiesterase, has been described in human platelets. Elevated cAMP levels regulate intracellular calcium concentrations by stimulating calcium removal, and thus platelet aggregation is ultimately inhibited by the reduction of cytoplasmic calcium, upon which platelet shape change, aggregation and the release reaction depends.

#### Pharmacodynamic effects

An infusion of 4 ng/kg/min for 30 minutes has been shown to have no significant effect on heart rate or blood pressure, although facial flushing may occur at this level.

### **Pulmonary Arterial Hypertension**

Intravenous epoprostenol infusions of up to 15 minutes have been found to produce dose-related increases in cardiac index (CI) and stroke volume (SV), and dose-related decreases in pulmonary vascular resistance (PVR), total pulmonary resistance (TPR) and mean systemic arterial pressure (SAPm). The effects of epoprostenol on mean pulmonary artery pressure (PAPm) in patients with idiopathic or heritable PAH were variable and minor.

Chronic continuous infusions of epoprostenol in patients with idiopathic or heritable PAH were studied in 2 prospective, open, randomised trials of 8 and 12 weeks' duration (N=25 and N=81, respectively) comparing epoprostenol plus conventional therapy to conventional therapy alone. Conventional therapy varied among patients and included some or all of the following: anticoagulants in essentially all patients, oral vasodilators, diuretics, and digoxin in one half to two thirds of patients; and supplemental oxygen in about half the patients. Except for 2 New York Heart Association (NYHA) functional Class II patients, all patients were either functional Class III or Class IV. As results were similar in the 2 studies, the pooled results are described. The combined baseline 6-minute walk test (6MWT) median value for the conventional therapy group and epoprostenol plus conventional therapy group was 266 meters and 301 meters, respectively.

Improvements from baseline in cardiac index (0.33 vs. -0.12 L/min/m<sup>2</sup>), stroke volume (6.01 vs. -1.32 mL/beat), arterial oxygen saturation (1.62 vs. -0.85%), mean pulmonary artery pressure (-5.39 vs. 1.45 mm Hg), mean right atrial pressure (-2.26 vs. 0.59 mm Hg), total pulmonary resistance (-4.52 vs. 1.41 Wood U), pulmonary vascular resistance (-3.60 vs. 1.27 Wood U), and systemic vascular resistance (-4.31 vs. 0.18 Wood U) were statistically different between patients who received epoprostenol chronically and those who did not. Mean systemic arterial pressure was not significantly different between the 2 groups (-4.33 vs. -3.05 mm Hg). These haemodynamic improvements appeared to persist when epoprostenol was administered for at least 36 months in an open, non-randomised study.

Statistically significant improvement was observed in exercise capacity (p=0.001), as measured by the 6MWT in patients receiving continuous intravenous epoprostenol plus conventional therapy (N=52) for 8 or 12 weeks compared to those receiving conventional therapy alone ([N=54] combined week 8 and 12 change from baseline - median: 49 vs. -4 meters; mean: 55 vs. -4 meters). Improvements were apparent as early as the first week of therapy. At the end of the treatment period in the 12-week study, survival was improved in NYHA functional Class III and Class IV patients. Eight of 40 (20%) patients receiving conventional therapy alone died, whereas none of the 41 patients receiving epoprostenol died (p=0.003).

Chronic continuous infusions of epoprostenol in patients with PAH/SSD were studied in a prospective, open, randomised trial of 12 weeks' duration comparing epoprostenol plus conventional therapy (N=56) to conventional therapy alone (N=55). Except for 5 NYHA functional Class II patients, all patients were either functional Class III or Class IV. Conventional therapy varied among patients and included some or all of the following: anticoagulants in essentially all patients, supplemental oxygen and diuretics in two thirds of the patients, oral vasodilators in 40% of the patients, and digoxin in a third of the patients. The primary efficacy

endpoint for the study was improvement in the 6MWT. The median baseline value for the conventional therapy group and epoprostenol plus conventional therapy group was 240 meters and 270 meters, respectively. A statistically significant increase in CI, and statistically significant decreases in PAPm, RAPm, PVR, and SAPm after 12 weeks of treatment were observed in patients who received epoprostenol chronically compared to those who did not.

Over 12 weeks, a statistical difference ( $p < 0.001$ ) in the change from baseline for the 6MWT was observed in the group receiving epoprostenol and conventional therapy as compared to the group receiving conventional therapy alone (median: 63.5 vs. -36.0 meters; mean: 42.9 vs. -40.7 meters).

Improvements were apparent in some patients at the end of the first week of therapy. Increases in exercise capacity were accompanied by statistically significant improvements in dyspnoea, as measured by the Borg Dyspnea Index. At week 12, NYHA functional class improved in 21 of 51 (41%) patients treated with epoprostenol compared to none of the 48 patients treated with conventional therapy alone. However, more patients in both treatment groups (28/51 [55%] with epoprostenol and 35/48 [73%] with conventional therapy alone) showed no change in functional class, and 2/51 (4%) with epoprostenol and 13/48 (27%) with conventional therapy alone worsened.

No statistical difference in survival over 12 weeks was observed in PAH/SSD patients treated with epoprostenol as compared to those receiving conventional therapy alone. At the end of the treatment period, 4 of 56 (7%) patients receiving epoprostenol died, whereas 5 of 55 (9%) patients receiving conventional therapy alone died.

The Phase 4 study AC-066A401 (EPITOME-1) was conducted in a total of 30 injectable prostanoid-naïve patients with PAH in NYHA functional class III or IV randomized to either Flolan ( $n = 10$ ) or Veletri® ( $n = 20$ ) for an open-label treatment period of 28 days. At Day 28 patients on both treatments were either maintained at the same NYHA functional class or improved compared to baseline. The results of the 6MWT were variable for the two groups and suggested no difference between treatments. The most frequently reported AEs were jaw pain, headache, flushing and diarrhea, which is consistent with the known safety profile of intravenous epoprostenol.

AC-066A301 (EPITOME-2) was a prospective, multicenter, single-arm, open-label, Phase 3b study in 41 patients with PAH to assess the effects of switching treatment from Flolan to Veletri®. Patients were hospitalized and switched from Flolan to Veletri® at the same dose at Day 1 and treated for 90 days. Exploratory evaluation of the change from baseline in cardiac hemodynamics, exercise capacity, NYHA FC, Borg dyspnea score and NT-proBNP three months after switch from Flolan showed that these variables were largely maintained over the treatment period, with similar values at baseline and EOT.

Exploratory evaluation of treatment satisfaction based on the TSQM-9 suggested an increase in treatment satisfaction relating to the convenience of using Veletri® three months after switch from Flolan, while the effectiveness and global satisfaction scores remained largely unchanged. The study was extended for long-term safety and tolerability evaluation (study AC-066A302).

The AE profile of Veletri® based on the data from AC-066A301/302 (EPITOME-2 and its extension study) was consistent with the AE profile of intravenously administered epoprostenol and not unexpected in this patient population. The most frequently reported AEs were headache, nasopharyngitis, pain in extremity, dyspnea, pain in jaw, bronchitis, diarrhea, fatigue, flushing, and AEs associated with the use of a drug-delivery device for continuous intravenous administration.

## 5.2 Pharmacokinetic properties

Due to the chemical instability, high potency and short half-life of epoprostenol, no precise and accurate assay has been identified as appropriate for quantifying epoprostenol in biological fluids.

Intravenously administered epoprostenol is rapidly distributed from blood to tissue.

At normal physiological pH and temperature, epoprostenol breaks down spontaneously to 6-oxo-prostaglandin F<sub>1</sub> alpha, although there is some enzymatic degradation to other products.

Following the administration of radiolabelled epoprostenol to humans, at least 16 metabolites were found, 10 of which were structurally identified.

Unlike many other prostaglandins, epoprostenol is not metabolised during passage through the pulmonary circulation.

The half-life for the spontaneous breakdown to 6-oxo-prostaglandin F<sub>1</sub> alpha in man is expected to be no more than 6 minutes, and may be as short as 2 to 3 minutes, as estimated from *in vitro* rates of degradation of epoprostenol in human whole blood.

Following the administration of radiolabelled epoprostenol to humans, the urinary and faecal recoveries of radioactivity were 82% and 4%, respectively.

## 5.3 Preclinical safety data

Non-clinical data revealed no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, and toxicity to reproduction and development. No long-term animal studies have been conducted to determine the carcinogenic potential of epoprostenol.

## 6. PHARMACEUTICAL PARTICULARS

### 6.1 List of excipients

Sucrose  
Arginine  
Sodium hydroxide (for pH adjustment)

### 6.2 Incompatibilities

This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.

### 6.3 Shelf life

3 years

*In use shelf life reconstituted/diluted solution for infusion:*

The reconstituted solution should be immediately further diluted to the final concentration.

The diluted solution should be stored in the drug delivery reservoir in order to protect from light and can be stored for up to 8 days at 2 to 8°C.

### 6.4 Special precautions for storage

Do not store above 30°C. Do not freeze. Keep out of the sight and reach of children.

The reconstituted solution should be immediately further diluted to the final concentration. (see section 4.2, section 6.3 and section 6.6).

Veletri® diluted to the final concentration in the drug delivery reservoir as directed can be administered at room temperature (25°C) immediately after dilution or after storage for up to 8 days at 2 to 8°C as per the conditions of use outlined in Table 2 section 6.6. Do not expose the fully diluted solution to direct sunlight.

## 6.5 Nature and contents of container

*Powder for solution for infusion:*

10 mL colourless glass type I vial closed with a rubber stopper and an aluminium flip-off cap (with a white disc for the 0.5 mg/vial strength, and a red disc for the 1.5 mg/vial strength).

Pack presentations:

Pulmonary Arterial Hypertension

There are 2 presentations available for use in the treatment of pulmonary arterial hypertension, as follows:

- One 0.5 mg powder vial.
- One 1.5 mg powder vial.

Not all pack sizes may be marketed.

## 6.6 Special precautions for disposal and other handling

- CADD-Legacy® 1
- CADD-Legacy® PLUS
- CADD®-Solis VIP (variable infusion profile)

Manufactured by Smiths Medical.

Pump accessories found to be compatible with the administration of VELETRI® include:

- CADD disposable Medication Cassette Reservoir 50 mL; 100 mL from Smiths Medical.
- CADD extension set with in-line 0.2 micron filter (CADD extension set with male luer, 0.2- micron air-eliminating filter, clamp, and integral anti-siphon valve with male luer) from Smiths Medical.

It is recommended that the infusion pump is not carried in permanent contact with the skin in order to avoid temperature excursions of the cassette.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

The stability of solutions of Veletri® is pH dependent.

The powder for solution for infusion must be reconstituted using either Sterile Water for Injection or Sodium Chloride 0.9% Injection solution.

Further dilution should be performed with the same diluent as used for reconstitution of the sterile, lyophilised powder.

### **Reconstitution, dilution and calculation of infusion rate:**

Particular care should be taken in the preparation of the infusion and in calculating the rate of infusion. The procedure given below should be closely followed.

Reconstitution and dilution must be carried out under aseptic conditions.

### **Reconstitution:**

Withdraw 5 mL of either Sterile Water for Injection or Sodium Chloride 0.9% Injection diluent into a sterile syringe, inject the contents of the syringe into the vial containing Veletri® and shake gently until the powder

has dissolved. The reconstituted solution should be examined prior to further dilution. Its use is forbidden in the presence of discolouration or particles. Any unused reconstituted solution should be disposed of in accordance with local requirements.

**Dilution:**

The reconstituted solution should be immediately further diluted to the final concentration. Further dilution should be performed with the same diluent as used for reconstitution of the sterile, lyophilised powder.

**Calculation of infusion rate:**

Infusion rates may be calculated using the following formula:

$$\text{Infusion rate (mL/min)} = \frac{\text{Dosage (ng/kg/min)} \times \text{bodyweight (kg)}}{\text{Concentration of solution (ng/mL)}}$$

$$\text{Infusion rate (mL/h)} = \text{Infusion rate (mL/min)} \times 60$$

A commonly used dilution is 2000 ng/mL Veletri®:

Dosage (ng/kg/min)	Bodyweight (kg)							
	30	40	50	60	70	80	90	100
1	0.90	1.20	1.50	1.80	2.10	2.40	2.70	3.00
2	1.80	2.40	3.00	3.60	4.20	4.80	5.40	6.00
3	2.70	3.60	4.50	5.40	6.30	7.20	8.10	9.00
4	3.60	4.80	6.00	7.20	8.40	9.60	10.80	12.00
5	4.50	6.00	7.50	9.00	10.50	12.00	13.50	15.00
Flow rates in mL/h								

There are 2 packs available for use in the treatment of pulmonary arterial hypertension, as follows:

- One vial containing sterile, freeze-dried Veletri® equivalent to 0.5 mg Veletri® supplied alone.
- One vial containing sterile, freeze-dried Veletri® equivalent to 1.5 mg Veletri® supplied alone.

**Reconstitution:**

Withdraw 5 mL of either Sterile Water for Injection or Sodium Chloride 0.9% Injection diluent into a sterile syringe, inject the contents of the syringe into the vial containing Veletri® and shake gently until the powder has dissolved. The reconstituted solution should be examined prior to further dilution. Its use is forbidden in the presence of discolouration or particles. Any unused reconstituted solution should be disposed of in accordance with local requirements.

**Dilution:**

The reconstituted solution should be immediately further diluted to the final concentration. Further dilution should be performed with the same diluent as used for reconstitution of the sterile, lyophilised powder. Veletri® when administered chronically, should be prepared in a drug delivery reservoir appropriate for the infusion pump. Only extension sets with an in-line 0.22 micron filter placed between the infusion pump and the catheter must be used. It is recommended to use filters with a hydrophilic polyethersulfone membrane. The extension set and the in-line filter must be changed at least every 48 hours (see section 4.4).

The vial containing 0.5 mg epoprostenol must be used for the preparation of solutions with final concentrations below 15,000 ng/mL.

Table 1 provides examples for preparing frequently used concentrations of Veletri® solutions. Each vial is for single use only.

Table 1: Frequently used concentrations – Examples of Reconstitution and Dilution

<b>Final Concentration (ng/mL)</b>	<b>Directions:</b>
3000 ng/mL	Dissolve contents of one 0.5 mg vial with 5 mL of either Sterile Water for Injection or Sodium Chloride 0.9% Injection. Withdraw 3 mL of the vial contents and add to a sufficient volume of the identical diluent to make a total of 100 mL.
5000 ng/mL	Dissolve contents of one 0.5 mg vial with 5 mL of either Sterile Water for Injection, or Sodium Chloride 0.9% Injection. Withdraw entire vial contents and add to a sufficient volume of the identical diluent to make a total of 100 mL.
10,000 ng/mL	Dissolve contents of two 0.5 mg vials, each with 5 mL of either Sterile Water for Injection or Sodium Chloride 0.9% Injection. Withdraw entire vial contents and add to a sufficient volume of the identical diluent to make a total of 100 mL.
15,000 ng/mL*	Dissolve contents of one 1.5 mg vial with 5 mL of either Sterile Water for Injection or Sodium Chloride 0.9% Injection. Withdraw entire vial contents and add to a sufficient volume of the identical diluent to make a total of 100 mL.
30,000 ng/mL*	Dissolve contents of two 1.5 mg vials, each with 5 mL of either Sterile Water for Injection or Sodium Chloride 0.9% Injection. Withdraw entire vial contents and add to a sufficient volume of the identical diluent to make a total of 100 mL.
30,000 ng/mL*	Dissolve contents of one 1.5 mg vial with 5 mL of either Sterile Water for Injection or Sodium Chloride 0.9% Injection. Withdraw entire vial contents and add to a sufficient volume of the identical diluent to make a total of 50 mL.
* Solutions with higher final concentrations may be necessary for patients who receive long-term administration of Veletri®.	

Veletri® diluted to the final concentration in the drug delivery reservoir as directed can be administered immediately at room temperature (25°C) or, if stored, for up to 8 days at 2 to 8°C as per the conditions of use outlined in Table 2.

Table 2: Maximum duration of administration (hours) at room temperature (25°C) of fully diluted solutions stored in the drug delivery reservoir

<b>Final concentration range</b>	<b>Immediate administration</b>	<b>If stored for up to 8 days at 2 to 8°C</b>
≥ 3000 ng/mL and <15,000 ng/mL	48 hours	24 hours
≥ 15,000 ng/mL	48 hours	48 hours

Do not expose the fully diluted solution to direct sunlight.

#### **Calculation of infusion rate:**

Infusion rates may be calculated using the following formula:

$$\text{Infusion rate (mL/min)} = \frac{\text{Dosage (ng/kg/min)} \times \text{bodyweight (kg)}}{\text{Concentration of solution (ng/mL)}}$$

$$\text{Infusion rate (mL/h)} = \text{Infusion rate (mL/min)} \times 60$$

Examples for some concentrations commonly used in pulmonary arterial hypertension are shown below.

Table 3: Infusion Rates for Veletri® at a Concentration of 5000 ng/mL

Example For Dosing Using a Concentration of 5000 ng/mL										
Dosage (ng/kg/min)	Bodyweight (kg)									
	10	20	30	40	50	60	70	80	90	100
2				1.0	1.2	1.4	1.7	1.9	2.2	2.4
4		1.0	1.4	1.9	2.4	2.9	3.4	3.8	4.3	4.8
6		1.4	2.2	2.9	3.6	4.3	5.0	5.8	6.5	7.2
8	1.0	1.9	2.9	3.8	4.8	5.8	6.7	7.7	8.6	9.6
10	1.2	2.4	3.6	4.8	6.0	7.2	8.4	9.6	10.8	12.0
12	1.4	2.9	4.3	5.8	7.2	8.6	10.1	11.5	13.0	14.4
14	1.7	3.4	5.0	6.7	8.4	10.1	11.8	13.4	15.1	16.8
16	1.9	3.8	5.8	7.7	9.6	11.5	13.4	15.4	17.3	19.2
	Flow rates in <b>mL/h</b>									

Table 4: Infusion Rates for Veletri® at a Concentration of 15,000 ng/mL

Example For Dosing Using a Concentration of 15,000 ng/mL								
Dosage (ng/kg/min)	Bodyweight (kg)							
	30	40	50	60	70	80	90	100
4				1.0	1.1	1.3	1.4	1.6
6		1.0	1.2	1.4	1.7	1.9	2.2	2.4
8	1.0	1.3	1.6	1.9	2.2	2.6	2.9	3.2
10	1.2	1.6	2.0	2.4	2.8	3.2	3.6	4.0
12	1.4	1.9	2.4	2.9	3.4	3.8	4.3	4.8
14	1.7	2.2	2.8	3.4	3.9	4.5	5.0	5.6
16	1.9	2.6	3.2	3.8	4.5	5.1	5.8	6.4
	Flow rates in <b>mL/h</b>							

Table 5: Infusion Rates for Veletri® at a Concentration of 30,000 ng/mL

Example For Dosing Using a Concentration of 30,000 ng/mL									
Dosage (ng/kg/min)	Bodyweight (kg)								
	30	40	50	60	70	80	90	100	
6						1.0	1.1	1.2	
8				1.0	1.1	1.3	1.4	1.6	
10			1.0	1.2	1.4	1.6	1.8	2.0	
12		1.0	1.2	1.4	1.7	1.9	2.2	2.4	
14		1.1	1.4	1.7	2.0	2.2	2.5	2.8	
16	1.0	1.3	1.6	1.9	2.2	2.6	2.9	3.2	
	Flow rates in <b>mL/h</b>								

Higher dosages, and therefore, more concentrated solutions may be necessary with long-term administration of Veletri®.

**7. PRODUCT REGISTRANT**

Johnson & Johnson Pte Ltd  
2 Science Park Drive  
#07-13, Ascent  
Singapore Science Park 1  
Singapore 118222

**8. BATCH RELEASER**

Actelion Pharmaceuticals Ltd  
Gewerbstrasse 12/14/16  
4123 Allschwil  
Switzerland

**9. DATE OF REVISION OF THE TEXT**

28 November 2019 (CCDS 24 October 2019)